NCT06785636 2026-04-07
P300
Pathos AI, Inc.
Phase 1/2 Recruiting
Clinical Trials
14 trialsNCT04179864 2026-03-10
CELLO-1
Ipsen
Phase 1/2 Terminated
NCT02861573 2026-02-17
KEYNOTE-365
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT05367440 2025-12-08
PETRANHA
AstraZeneca
Phase 1/2 Active not recruiting
NCT07198633 2025-09-30
A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer
Qilu Pharmaceutical Co., Ltd.
Phase 1/2 Not yet recruiting
NCT03568656 2025-08-08
Study to Evaluate CCS1477 in Advanced Tumours
CellCentric Ltd.
Phase 1/2 Completed
NCT07104110 2025-08-05
Study of QLH12016 in Combination With Novel Hormonal Agent in Subjects With Advanced Prostate Cancer
Qilu Pharmaceutical Co., Ltd.
Phase 1/2 Not yet recruiting
NCT04556617 2025-04-08
PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Opna Bio LLC
Phase 1/2 Terminated
NCT01685268 2024-08-02
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
Astex Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT05405439 2023-11-03
To Evaluate the Efficacy of TQB3823 Combined With Abiraterone and Prednisone in Metastatic Castration-resistant Prostate Cancer Patientsprednisone Acetate Tablets in Patients With Metastatic Castration-resistant Prostate Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2 Terminated
NCT01511536 2016-07-28
Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer
Sanofi
Phase 1/2 Completed
NCT02049190 2015-06-24
Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer
Arno Therapeutics
Phase 1/2 Unknown
NCT00473746 2014-04-29
Abiraterone Acetate Dose-Escalation Study in Hormone Refractory Prostate Cancer
Janssen Research & Development, LLC
Phase 1/2 Completed
NCT00473512 2014-03-27
A Safety and Efficacy Study of Abiraterone Acetate in Participants With Prostate Cancer Who Have Failed Hormone Therapy
Cougar Biotechnology, Inc.
Phase 1/2 Completed